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Abstract objectives This longitudinal comparative study investigated the effect of preventive chemotherapy
(PC) on covert tissue changes associated with lymphatic filariasis (LF) among young people living in
an LF-endemic area in Myanmar.
methods Tissue compressibility and extracellular free fluid in the lower limbs of people aged 10–
21 years were measured using indurometry and bioimpedance spectroscopy (BIS). Baseline measures
were taken in October 2014, annual mass drug administration (MDA) of PC was delivered in
December, and in March 2015 further PC was offered to LF-positive cases who had missed MDA.
Follow-up measures were taken in February and June 2015.
results A total of 50 antigen-positive cases and 46 antigen-negative controls were included. Self-
reported PC consumption was 60.1% during 2014 MDA and 66.2% overall. At second follow-up,
24 of 34 cases and 27 of 43 controls had consumed PC. Significant and clinically relevant between-
group differences at baseline were not found post-PC. Bayesian linear mixed models showed a
significant change in indurometer scores at both calves for antigen-positive cases who consumed any
PC (dominant calf: 0.30 [95% CI 0.52, 0.07], P < 0.05 and non-dominant calf: 0.35 [95% CI
0.58, 0.12], P < 0.01). Changes in antigen-negative participants or those not consuming PC were
not significant.
conclusion This study is the first attempt to use simple field-friendly tools to track fluid and tissue
changes after treatment of asymptomatic people infected with LF. Results suggested that PC alone is
sufficient to reverse covert lymphatic disturbance. Longer follow-up of larger cohorts is required to
confirm these improvements and whether they persist over time. These findings should prompt
increased efforts to overcome low PC coverage, which misses many infected young people,
particularly males, who are unaware of their infection status, unmotivated to take PC and at risk of
developing lymphoedema. Indurometry and BIS should be considered in assessment of lymphatic
filariasis-related lymphedema.
keywords lymphedema, lymphatic filariasis, preventive chemotherapy, mass drug administration,
global programme to eliminate lymphatic filariasis, lower extremity, indurometry, bioimpedance
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Introduction
Lymphatic filariasis (LF) is a major cause of disability
and the most widespread of the neglected tropical dis-
eases [1]. Several mosquito species are capable of trans-
mitting microfilariae, and there are three main species of
worm, the most common being Wuchereria bancrofti
which is endemic in many countries throughout the west-
ern Pacific, Asia and Africa [2]. Home for the thread-like
worms is the human lymphatic system where they typi-
cally reside in worm nests established close to lymph
nodes in the groin. Of the two main sequelae, lym-
phedema and hydrocele, only hydrocele can be cured
with surgical intervention. Manifest lymphedema is irre-
versible and current estimates put the number of people
living with chronic filariasis-related lymphedema (FRL) at
16.7 million worldwide [3]. The global programme to
eliminate LF (GPELF) as a public health problem oper-
ates at two levels. To interrupt transmission of microfilar-
iae, annual mass drug administration (MDA) of
preventive chemotherapy (PC) is distributed to all resi-
dents in LF-endemic areas; WHO recommends PC cover-
age of 65% of the total population for 4–6 years. For
people who already have chronic disease, morbidity man-
agement and disability prevention (MMDP) services
should be provided [4].
Lymphedema is an accumulation of protein-rich fluid
in the skin and subcutaneous tissue that would normally
be removed by continuous pumping of the lymphatic ves-
sels [5]. In LF, host inflammatory responses to worm
antigen and the endosymbiotic Wolbachia bacteria can
lead to lymphatic insufficiency [6], but lymphedema can
also be caused by any damage or congenital malforma-
tion of the lymphatic system [7]. In breast cancer-related
lymphedema (BCRL) of the arm, the most researched
form of lymphedema, it is excision of lymph nodes in the
arm pit, radiation treatments and subsequent tissue scar-
ring that can disrupt lymph flow [8]. Whatever the cause,
the pathogenesis of lymphedema follows a largely pre-
dictable course. Early protein-rich fluid accumulation in
the tissue spaces is gradually replaced by hyperplasia of
fibrous and fatty tissue and enlargement of the affected
limb or body parts. In advanced stages, hyperkeratosis
gives the skin a thick and scaly appearance and ulcera-
tions and papillomatosis are common. As lymphedema
progresses from transient swelling to irreversible limb
enlargement, treatment becomes increasingly difficult and
resource-intensive [9]. Skin pathologies increase the risk
of secondary bacterial and fungal infections, and later
stages are associated with significant disability [10].
From studies on BCRL, it is known that onset of lym-
phedema can be delayed years or even decades after the
original exposure to the risk [11, 12] and a growing
body of evidence indicates that early detection and
intervention have the potential to reverse covert changes
and prevent lymphedema from forming [13–15]. This
has led to development of monitoring protocols in those
at risk of BCRL and employment of preventive interven-
tions before any overt symptoms appear [16]. In LF,
parasitic infection usually begins in childhood [17], and
children with LF typically remain asymptomatic until
young adulthood with a long interval between infection
and the onset of overt lymphedema. This presents an
extended period in which to identify those at risk of
progression and initiate preventive interventions, but in
contrast to guidelines for BCRL, GPELF recommenda-
tions do not attempt to identify or intervene in covert
FRL. The potential effectiveness of PC in reversing cov-
ert and early-stage disease has been reported in two
studies which both used a similar methodology [18, 19].
Both studies were on cohorts of 100 children with filar-
ial disease aged 5–18 years and both found that PC
medication reversed covert tissue changes (assessed by
lymphoscintigraphy) and some mild, overt lymphedema.
However, neither included a control group to assess the
effect over time of either no PC or PC on uninfected
individuals. Furthermore, one was conducted on children
with Brugia malayi infection [19] and both studies
involved 100% PC coverage, so neither would reflect
actual MDA coverage in countries endemic for W. ban-
crofti [18, 19].
All mainland South-East Asian countries are endemic
for LF [20]. In Myanmar, this includes 45 of the 64 dis-
tricts and the central western ‘dry zone’ is highly ende-
mic, with pre-MDA prevalence estimates of 20–30%
[21]. The mean national prevalence has fallen from 7.1%
in 2001 to 2.7% in 2011, but MDA coverage has been
inconsistent in some areas [20]. A recent survey of a rep-
resentative sample of individuals in Mandalay Region
indicated that PC was consumed, on average, fewer than
half of the six times MDA had been delivered between
2001 and 2015 [22]. A cross-sectional study in Myanmar
on asymptomatic young people infected with W. ban-
crofti found covert increases in tissue compressibility and
extracellular free fluid in the lower extremities of anti-
gen-positive young people compared to their antigen-
negative peers [23]. This confirmed similar findings of a
pilot study in an endemic region in Papua New Guinea
(PNG) where increased tissue compressibility was also
identified in lower limbs of young asymptomatic people
with LF [24].
The transient nature of these covert tissue changes in
relation to progression to FRL, or the effect of PC medi-
cations on covert disease in actual MDA conditions, has
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not been investigated. Therefore, we conducted a com-
parative cohort study to investigate changes in lower limb
tissue compressibility and extracellular free fluid in
asymptomatic individuals with different LF antigen status
before and after annual MDA in Mandalay Region,
Myanmar.
Methods
During October 2014 (Oct 14), a convenience sample of
young people aged 10–21 years residing in Amarapura
Township, Central Myanmar, was invited to be screened
for LF infection using a rapid field immunochromato-
graphic test (ICT) for the presence of W. bancrofti anti-
gen (Binax NOW, Alere, USA). Antigen-positive cases
and a similar cohort (by age and gender) of antigen-nega-
tive controls were invited to continue in the longitudinal
study. A timeline of study activities can be seen in Fig-
ure 1. The study was approved by the James Cook
University Human Research Ethics Committee approval
number H5261 and the Myanmar Ministry of Health
(now known as the Ministry of Health and Sports
(MOHS)).
Detailed accounts of sample size calculation, recruit-
ment, consent and screening methods have been reported
previously [23, 25]. The annual MDA, a single dose of
albendazole and diethylcarbamazine citrate (DEC) [26,
27], was distributed in Mandalay Region during Decem-
ber 2014 (Dec 14), and follow-up measures were
obtained during February 2015 (Feb 15). At this follow-
up, fewer than the recommended 65% of participants
reported PC consumption during the Dec 14 MDA. The
Myanmar MOHS was advised of this, and a course of
DEC (12 daily doses as per Myanmar MOHS policy) was
offered to positive cases (as detected by ICT) during
March 2015. Further follow-up data were then collected
in June 2015 (Jun 15).
Data collection
Procedures for physical measures and blood collection
used at baseline (Oct 14) [23] were repeated at each fol-
low-up. Local research assistants interviewed each partic-
ipant to ascertain any changes in their medical status and
recorded height and weight measures. Leg dominance
was determined by asking which leg was used to kick a
ball. A 10 ml venous blood sample was collected into a
cooled ethylenediaminetetraacetic acid (EDTA) anticoag-
ulant vacutainer (BD Biosciences, North Ryde, Australia)
and used to confirm the LF antigen status of all partici-
pants using Og4C3 ELISA (Cellabs, Australia). Detailed
blood collection and plasma handling procedures are
reported in the cross-sectional analysis of baseline data
[23] and in a report on the results of the serological anal-
yses [25].
The procedure for collecting device measures has also
been reported in detail [23, 28, 29]. A tape measure was
used to locate the mid-point of the anterior thigh, poste-
rior thigh and calf segments of each leg. An indurometer
(SA Biomedical Engineering, Australia) was used to
assess tissue compressibility at each of the marked mid-
points. This electromechanical device uses an indenter
pressed into the skin with a defined force to measure the
resistance (stiffness) or compliance (compressibility) in
the underlying skin and tissue. The hand-held unit has a
7-cm-diameter reference plate with a 1-cm-diameter
indenter. With the reference plate rested flat to the skin
over the marked point, the indenter is pushed into the
skin by the operator and a force sensor detects when the
equivalent to a 200 g force has been applied. The dis-
placement between the indenter and the reference plate
(to what extent the indenter is able to compress the
underlying tissue) is detected in 0.01 increments and dis-
played on a digital light-emitting diode (LED) screen.
This device has been previously shown to have excellent
October 2014 
Participant screening 
Baseline measures 
(Oct 14)
February 2015 
First follow-up 
measures 
(Feb 15)
June 2015 
Second follow-up 
measures 
(Jun 15)
December 2014 March 2015
Annual MDA DEC offered to antigen 
DEC and albendazole positive cases 
Figure 1 Timeline of data collection activities.
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reliability in uninfected young people in Australia and
Myanmar [28].
Whole leg extracellular free fluid was assessed by BIS
using the SBF7 (Impedimed, Australia), a portable bat-
tery-operated device. Self-adhesive electrodes were placed
on the skin according to the manufacturers’ instructions
for whole-limb analysis. When the device is activated, a
multifrequency low-level current passes between the elec-
trodes and through the epifascial compartment. The resis-
tances (impedance) in the extracellular and intracellular
fluid compartments are recorded separately and expressed
as a ratio of ICF:ECF (Ri:Re). Images of the indurometer
and SBF7 and their use in Myanmar can be seen in addi-
tional Figures S1 and S2.
At baseline (Oct 14), participants were asked whether
they had consumed PC during the previous MDA
(September 2013). After device measures and blood sam-
ples had been collected, advice was given to each partici-
pant and the attending guardian of minors on their LF
status and the importance of everyone – regardless of
infection status – consuming the PC which would be
offered during the 2014 MDA (the following December).
At the Feb 15 follow-up, they were asked about their
participation in the 2014 MDA, and at the Jun 15 fol-
low-up, they were asked whether they had consumed the
additional PC medication offered in March.
Data on average monthly temperature and relative
humidity for Amarapura Township were collected
retrospectively using an online source [30]. The average
monthly temperature and humidity data were used to
estimate the heat index for each time point using an
online calculator [31]. A heat index can be used to deter-
mine the risk of heat stress in varying conditions [32].
Analysis
A sample size of 32 in each group was calculated to
detect a 10% difference between groups at baseline with
80% power, based on a mean mid-calf indurometer value
of 2.5 with SD of 0.7 [23, 29]. BMI was calculated using
the formula kg/m2, and participants were classified as
underweight if they were more than two standard devia-
tions below the mean BMI-for-age using WHO defini-
tions and growth tables [33]. Systemic hydration was
approximated by the length of time since the last drink
was taken with less than or more than 60 min defining
the more- or less-hydrated groups, respectively. Con-
sumption of PC was determined by self-report.
At each time point, participant characteristics and
device scores were analysed using independent t-tests to
identify any between-infection group differences, and
one-way ANOVA was used to compare within-group
characteristics over three time points. t-Tests and one-
way ANOVA were performed using SPSS (v24, IBM
Corp). A clinically relevant difference in device score was
determined as ≥ 5% for indurometer measures [7] and
Figure 2 Map of Amarapura Township area (coloured) showing the village tracts (shaded) where study participants were resident at
the time of recruitment into the cross-sectional study. Mandalay city centre is also identified (star).
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≥3% for BIS measures [13]. Device scores were further
analysed using Bayesian linear mixed models to account
for time, age, gender, BMI, infection status and PC con-
sumption. Study participants were specified as partici-
pant-level random intercepts. Leg dominance is known to
influence device measures [29, 34], and therefore, before
and after comparisons were considered by individual
limb. The R statistical software v.3.4.4 was used to per-
form the analyses [35]. Bayesian linear mixed models
were fit with the Stan program v.2.17.0 [36] through the
Rstan v.2.17.3 [37] and brms v.2.2.0 [38] interfaces.
Participants
Volunteers (n = 104) at baseline (Oct 14) were resident
in 11 villages in Amarapura Township located within the
village tracts shown on the map in Figure 2 [39]. All data
were collected out at the Nge Toe Village administration
centre.
A flow chart of participants through the study is pro-
vided in Figure 3. Participants were classified as LF anti-
gen-positive if they were positive by either ICT or Og4C3
(confirmed by repeat tests) [23]. Data from two controls
that tested negative by ICT were excluded from analysis
due to discordant Og4C3 results on repeat testing as this
discrepancy could not be resolved. At the Feb 15 follow-
up, eight participants could not be found or declined to
return. At the Jun 15 follow-up, four people who had
missed the Feb 15 follow-up presented for measures, but
14 others could not be found or did not return for
unknown reasons. At the Jun 15 follow-up, one partici-
pant revealed that she was five months pregnant which
meant that she had been pregnant during the Feb 15 fol-
low-up measures but not at baseline and her data set was
excluded from the follow-up analysis. This provided 96
participants at baseline, 87 participants at the Feb 15 fol-
low-up and 77 participants at the Jun 15 follow-up for
the longitudinal analysis.
Participant characteristics are given in Table 1. At
baseline, the mean cohort age was 15.3 (SD 3.41) years
and 55.2% were female. There were no significant
between-infection group differences for age, gender,
height, weight, BMI, BMI-for-age, occupation (student or
working), time since the last menstrual period (females
≥14 days since last menses) or hydration (drank ≤60 min
before the measures were taken) and this remained true
at the Feb 15 and Jun 15 follow-ups. Between-infection
group characteristics at each time point are given in addi-
tional Table S1. Within-infection group characteristics
did not change significantly over time other than the level
of recent hydration (see Table 1). At the Jun 15 follow-
up, significantly more people had consumed a drink
within the hour prior to measurement in both groups
than at baseline (whole cohort; Oct 14 26.0%, Jun 15
59.7%, P < 0.000).
Consumption of PC
At the first follow-up (Feb 15), 60.1% of all returning
participants reported they had taken PC during the 2014
MDA. Table 2 shows the PC consumption for antigen-
positive and antigen-negative groups and by gender.
There was no significant between-infection group differ-
ence in the proportion of PC consumed during the 2014
MDA (antigen-positive 59.5% and antigen-negative
62.2%, P = 0.800); however, there were large differences
between consumption by sex (male = 29.7%,
female = 64% P = 0.392.). At the Jun 15 follow-up after
the ICT-positive cases were offered further PC, a total of
66.2% of participants had taken PC either during the
2014 MDA or in March 2015.
Device measures
There was a prevailing pattern of tissue compressibility at
all time points. Highest indurometer values (most com-
pressible tissue) were always found over the anterior
thighs, and the lowest values (stiffest tissue) were always
at the mid-calf where there is little underlying fat. Whole
leg free fluid was higher in the dominant leg. This pattern
of tissue compressibility and free fluid in the lower limbs
is consistent with previous reports on young people with-
out infection in Australia and Myanmar [29]. Whole
cohort mean values for indurometer and BIS scores at all
time points are provided in additional Table S2.
There was significant variation in unadjusted device
scores for the whole cohort associated with time, but the
direction of the association was not consistent with natu-
ral linear growth (see Figure 4a,b). Rather, a nonlinear
effect was detected where tissue compressibility was
lower and free fluid was higher at the Feb 15 follow-up
than at baseline, but this had reversed again at the Jun
15 follow-up. Compared to baseline, at the Jun 15 fol-
low-up there was a significant increase in tissue com-
pressibility at the dominant anterior thigh (9.1%,
P < 0.000) (Figure 4a), and a statistically and clinically
significant reduction in free fluid in both legs (dominant
leg 13.6%, P < 0.000) (non-dominant leg 7.7%,
P = 0.019) (Figure 4b).
Myanmar has a range of climate regions from tropical
monsoons in the south to subtropical highlands in the
north. Mandalay Region, in Central Myanmar, is known
as the dry zone and classified as hot and semi-arid by the
K€oppen–Geiger scale [40]. Baseline data were collected in
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Data collected at Baseline (Oct 14)
n = 104
Data excluded
Older than 21 years n = 4
Participants included in Baseline analysis n = 96
Antigen positive by ICT & Og4C3 ELISA n = 46  
Antigen negative by ICT, positive by Og4C3 ELISA n = 4
Total antigen positive n = 50 
Antigen negative by ICT & Og4C3 ELISA n = 46
Baseline data included in the follow up analysis Oct 14 n = 96
Antigen positive n = 50
Antigen negative n = 46
Data excluded
Pregnant = 1
Lost to Feb 15 follow-up
Not found or declined n = 8
Data available at first follow-up
Feb 15 n = 87
•    Consumed PC during MDA n = 28
Lost to Jun 15 follow-up
2015 DEC offered
to antigen-positive
No present at Feb 15 follow-up
Returned at Jun 15 n = 4
Data included in the follow up analysis
Antigen positive cases n = 34
•   Consumed any PC n = 24
Jun 15 n = 77
Antigen negatvie controls n = 43
•    Consumed any PC n = 27
Prosthetic leg n = 1
Not found or declined n = 14
participants
Antigen positive n = 42 Antigen negative n = 45
Consumed PC during MDA n = 25
2014 MDA
Heart condition n = 1
Unresolved antigen status
results n = 2
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
Figure 3 Flow chart of participants through the study. [Colour figure can be viewed at wileyonlinelibrary.com]
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October at the end of the rainy season, the Feb 15 fol-
low-up was in the middle of the cool dry season, and Jun
15 follow-up measures were taken during the hot, humid
build-up to the wet season. Average monthly tempera-
ture, relative humidity and the heat index score for each
data collection time are shown in Table 3.
Comparison of device scores between-infection groups
at baseline (Oct 14) was previously reported [23] and
showed that antigen-positive cases had higher tissue com-
pressibility at all measuring points, and more free fluid in
both legs, than their antigen-negative peers. This was
both clinically relevant and statistically significant for
indurometer scores at the non-dominant calf. Unadjusted
between-infection group comparisons at the Jun 15 fol-
low-up showed that tissue compressibility was still higher
among the positive cases at both calves, and free fluid
was higher in the dominant leg but none were statistically
significant. Figure 5a summarises the unadjusted
between-group differences at baseline (Oct 14) and sec-
ond follow-up (Jun 15) for indurometer scores and Fig-
ure 5b for BIS scores.
Previous reports on indurometry and BIS measures in
the lower limbs of young people have identified moder-
ating factors associated with variation in device scores.
Linear regression was used to determine factors associ-
ated with variation in device scores in this cohort, and
results were consisted with previous reports [23, 29].
Results of the linear regression for age, gender, body
composition and recent hydration are given in addi-
tional Table S3. In summary, over the nine months of
Table 1 Group characteristics and moderating factors at three time points
Participant characteristic Ag status
Oct 14 n = 96
Ag n = 46
Ag+ n = 50
Feb 15 n = 87
Ag n = 45
Ag+ n = 42
Jun 15 n = 77
Ag n = 43
Ag+ n = 34 P
Age in years, mean (SD) Negative 15.41 (3.47) 15.33 (3.30) 16.28 (3.35) 0.350†
Positive 15.20 (3.38) 14.98 (3.50) 15.38 (3.68) 0.879†
Female, n = (%) Negative 26 (56.5%) 27 (60.0%) 28 (65.1%) 0.707‡
Positive 27 (54.0%) 23 (54.8%) 22 (64.7%) 0.579‡
Height in cm, mean (SD) Negative 152.55 (11.65) 153.28 (11.34) 154.10 (9.58) 0.798†
Positive 151.80 (12.56) 151.56 (12.57) 149.65 (12.07) 0.712†
Weight in kg, mean (SD) Negative 42.62 (10.16) 44.05 (9.81) 44.61 (9.30) 0.612†
Positive 42.27 (12.81) 43.29 (12.98) 40.36 (11.83) 0.598†
BMI, mean (SD) Negative 18.04 (2.79) 18.50 (2.68) 18.67 (2.78) 0.531†
Positive 18.04 (3.33) 18.40 (3.36) 17.57 (3.23) 0.562†
Underweight for age n = (%) Negative 6 (13.0%) 6 (13.3%) 3 (7.0%) 0.567‡
Positive 7 (14.0%) 5 (11.9%) 7 (20.6%) 0.554‡
Occupation, student n = (%) Negative 13 (28.3%) 12 (26.7%) 9 (20.9%) 0.609‡
Positive 14 (28.0%) 14 (33.3%) 9 (26.4%) 0.152‡
Menstruation ≥ 2 weeks n = (%) Negative 7 (26.9%) 5 (18.5%) 7 (25.0%) 0.597‡
Positive 8 (16.0%) 9 (21.4%) 2 (5.9$) 0.425‡
Hydration ≤ 60 min n = (%) Negative 12 (26.1%) 19 (42.2%) 26 (60.5%) 0.016‡
Positive 13 (26.0%) 15 (35.7%) 20 (58.8%) 0.009‡
Ag, antigen status; BMI, body mass index; SD, standard deviation.
†One-way ANOVA.
‡Pearson chi-square.
Table 2 Self-reported consumption of PC by infection group and sex
Participants 2013 MDA 2014 MDA 2014 MDA or DEC
Antigen-negative All n = (%) 22 (47.8%) 28 (62.2%) 27 (62.8%)
Males n = (%) 13 (65.0%) 2 (11.1%) 11 (73.3%)
Females n = (%) 9 (34.6%) 16 (59.3%) 16 (57.1%)
Antigen-positive All n = (%) 17 (34.0%) 25 (59.5%) 24 (70.6%)
Males n = (%) 15 (65.2%) 9 (47.4%) 8 (66.7%)
Females n = (%) 2 (7.4%) 16 (69.6%) 16 (72.7%)
DEC, diethylcarbamazine citrate; MDA, mass drug administration of albendazole and DEC.
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the study, there was an association with increased age
and small increases in tissue compressibility and
increased free fluid. Being female was significantly asso-
ciated with increased tissue compressibility and less free
fluid in both legs, and all associations were large
enough to be considered clinically relevant and statisti-
cally significant. There were notable associations with
being underweight and increased free fluid in both legs
and between less recent hydration and increased tissue
stiffness.
Effects of preventive chemotherapy
A Bayesian linear mixed model was used to determine
the marginal effect of PC consumption on device scores
over time. There was a significant change in indurometer
scores at both calves for antigen-positive cases who con-
sumed any PC (dominant calf: 0.30 [95% CI 0.52,
0.07], P < 0.05 and non-dominant calf: 0.35 [95% CI
0.58, 0.12], P < 0.01). Changes in all scores for anti-
gen-positive cases who consumed any PC are given in
7.00
6.00
5.00
4.00
3.00
2.00
1.00
0.00
Dominant
Dominant limb Non-dominant limb
Non-dominant Dominant Non-dominant Dominant Non-dominant
Anterior thigh Posterior thigh
Oct 14 Feb 15 Jun 15
Oct 14 Feb 15 Jun 15
Calf
4.00
3.00
3.50
2.00
2.50
1.00
1.50
0.00
2.50 2.50 2.84
SBF7 - Whole Cohort
4.73 4.42 5.16 5.04 4.31 5.08 4.09 3.20 4.14 3.85 3.30 4.05 2.80 1.95 2.75 2.59 2.00 2.73
Indurometer - Whole Cohort
2.74 2.52 2.94
0.50
**
**
(a)
(b)
Figure 4 (a) Whole cohort mean indurometer scores for each measurement site at all three time points. Higher values = higher tissue
compressibility. **P < 0.000, *P < 0.05 Oct 14 vs. Jun 15. (b) Whole cohort mean BIS scores for each leg at all three time points.
Higher values = less extracellular free fluid. **P < 0.000, *P < 0.05 Oct 14 vs. Jun 15.
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additional Table S4. Figures 6a,b shows box and whisker
plots of the marginal effects for all device scores in anti-
gen-positive and antigen-negative groups who did or did
not consume PC (either during the 2014 MDA or March
2015). Considering the non-dominant calf where the
between-group differences had been significant at base-
line, the box plots suggest that there was little change in
tissue compressibility among antigen-negative participants
who did or did not take any PC. However, antigen-posi-
tive cases who did not take PC had small increases in tis-
sue compressibility while those who had taken PC (either
at the 2014 MDA or in March 2015) had a significant
reduction in tissue compressibility (Figure 6a).
Likewise, among antigen-positive cases who took any
PC, free fluid, which had been higher in both legs than in
their antigen-negative peers at baseline, was reduced in
Jun 15. For antigen-positive cases who had not taken PC,
there was little change, and for antigen-negative controls,
the non-dominant leg had an increase in free fluid while
the dominate leg had remained the same, although none
of these changes were statistically significant (Figure 6b).
The direction of these changes in tissue compressibility
and free fluid among antigen-positive participants who
had consumed any PC suggests that some of the covert
tissue changes associated with LF antigenaemia which
had been found at baseline had resolved by the Jun 15
follow-up.
Discussion
It was previously shown that young Myanmar people
who were LF antigen-positive but asymptomatic had
covert increases in both tissue compressibility and free
fluid in the lower limbs compared to their antigen-nega-
tive peers [23]. These changes were detected using an
indurometer and with bioimpedance spectroscopy (BIS)
and are consistent with an imperceptible accumulation
of fluid in the tissues such as occurs when lymphatic
transport is reduced. Similar covert changes have been
identified in the at-risk arm of women after breast can-
cer treatment using BIS. In the breast cancer population,
it has been shown that responding with a prophylactic
intervention (light compression sleeve) to a small
increase in free fluid (3%) prevents the onset of overt
lymphatic disease [13]. This study followed the Myan-
mar cohort longitudinally to assess the effect of PC, at
coverage levels recommend under GPELF, on indurom-
eter and BIS scores. There were significant absolute
changes in device scores in the antigen-positive group
who took any PC (either during the 2014 MDA or in
March 2015). The significant between-infection group
differences, which were detected before the 2014 MDA,
were not found at the Jun 15 follow-up, which suggests
that PC may have a beneficial effect on early fluid and
tissue changes in the lower limbs among young people
who are LF antigen-positive. PC consumption had little
or no effect on device scores among antigen-negative
cases while antigen-positive cases who did not consume
PC had further increases in tissue compressibility at
both calves.
Self-reported MDA participation in this cohort was
lower than the WHO-recommended coverage levels. Only
40.1% of participants reported taking PC during the
2013 MDA (see Table 2). Despite gaining knowledge of
their infection status in October 2014, and receiving
information on the importance of the MDA, the propor-
tion of young males who participated in the MDA in
December 2014 went down (antigen-positive males from
65.2% in 2013 to 47.4% in 2014 and antigen-negative
males from 65.0% in 2013 to 11.1% in 2014). Con-
versely, consumption went up among all females from
13.8% in 2013 to 64% in 2014, which could imply that
young women are more responsive to health-related
information. Preliminary reports on 2014 MDA partici-
pation reported in this cohort and a morbidity survey
conducted in Myanmar at the same time [22] were deliv-
ered to the Myanmar MOHS and greater emphasis has
been given to increasing community awareness of LF and
the MDA programme in the Mandalay Region since
2015 [41].
Variation associated with time constituted the greatest
proportion of the observed variation when all three time
points were included in the models. However, a causal
effect of season cannot be confirmed with current data,
Table 3 Average monthly temperature, humidity and heat index for Amarapura during each month of data collection
Average monthly
Humidity (%) Temperature (°C) Temp range (°C) Heat index Heat warning
Oct 14 72 31 35–24 39 Caution
Feb 15 36 29 34–19 28 No warning
Jun 15 60 34 38–29 42 Extreme caution
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Dark dots represent % differences 
Solid dots indicate positive cases had 
higher tissue compressibility 
Hollow dots indicate negative controls 
had higher tissue compressibility 
October 2014 
October 2014 October 2014 
October 2014 
October 2014 October 2014 
October 2014 
1.7% P = 0.701 
0.6% P = 0.837 
0.6% P = 0.832 
0.4% P = 0.933 
11.1% P = 0.21 
2.2% P = 0.608 
2.2% P = 0.645 
1.1% P = 0.731 
1.9% P = 0.546 
7.8% P = 0.096 
4.9% P = 0.220 
June 2015 June 2015 - 
June 2015 - June 2015 
June 2015 
Non-dominant leg 
Non-dominant leg 
Dominant leg 
Dominant leg 
June 2015 
June 2015 
0.2% P = 0.961 
6.7% P = 0.142
2.1% P = 0.644
between infection groups at Baseline 
between infection groups at Follow-up  
Pale dots represent %differences 
Dark dots represent % differences 
Solid dots indicate positive cases had 
more free fluids 
Hollow dots indicate negative controls 
had more free fluid 
between infection groups at Baseline 
between infection groups at Follow-up  
Pale dots represent %differences 
October 2014 
9.2% P = 0.053 
–0.3% P = 0.926 
June 2015 
(a)
(b)
Figure 5 (a) Unadjusted comparison of indurometer scores between-infection groups at baseline (Oct 14) and second follow-up (Jun
15). (b) Unadjusted comparison of BIS scores between-infection groups at baseline (Oct 14) and second follow-up (Jun 15).
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Figure 6 (a) Box and whisper plots showing the marginal change in indurometer scores. Higher scores indicate increased tissue com-
pressibility. (b) Box and whisper plots showing the marginal change in BIS scores. Higher scores indicate reduced free fluid.
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and this variation could be due to another unmeasured
factor. Nonetheless, tissue compressibility was signifi-
cantly reduced in the cooler months (first follow-up Feb
15) and increased during the hot humid weather at the
Jun 15 follow-up. This is consistent with the effect of sea-
sonal changes noted among women with BCRL in Aus-
tralia [42] where increased swelling was associated with
warmer temperatures on the day before measurement
(r = 0.27, P < 0.001). However, BIS scores indicated that
free fluid was higher during the cooler Feb 15 measures
but then reduced during the hot humid Jun 15 measures
which is in the opposite direction to what might be
expected, especially considering that significantly more
participants in both groups had reported having a drink
within the hour prior to measures. It may be that during
June in Central Myanmar, when the heat index indicated
extreme caution, it is difficult to remaining well hydrated.
This unanticipated limitation in study design (ambient
temperature and relative humidity were not recorded
within the data collection centre) highlights the impor-
tance of accounting for seasonal variation when assessing
tissue compressibility and extracellular free fluid. This
important variable may have been missed entirely if data
collection had stopped in February after the 2014 MDA
as originally planned. There are few published data
around the effect of weather on LF other than a 1998
report by Shenoy and colleagues [43] on an increase in
episodes of adeno-dermato-lymphangitis (acute attacks)
in Brugian filariasis during the rainy season in southern
India. How ambient temperature affects free fluid and tis-
sue compressibility in people with filariasis-related lym-
phoedema is not known.
Other limitations to this study were the poor MDA
coverage during the 2014 MDA, which required addi-
tional DEC (administered by the Myanmar MOHS) to
achieve more than the recommended 65% PC coverage
among the study population. This means the results are
not based on the before-and-after MDA data alone. The
study was also limited by the 26% dropout rate, which
was higher than expected and reduced the data available
for analysis at follow-up. Group sizes at follow-up were
large enough for analysis of between-infection groups,
but once subgroups such as sex and PC consumption
were considered, these became too small, and studies on
larger cohorts are required. The short time frame of nine
months was insufficient to definitively answer questions
regarding the reversal of early fluid and tissue changes
using MDA alone, and long-term follow-up on this and
future research cohorts would be ideal.
At the covert stage of lymphatic disease from LF, it is
unlikely that the lymphatic vessels themselves have under-
gone irreversible damage. Young people in particular
may recover fully if the cause, in this case the presence of
adult worms, can be removed as has been shown using
lymphoscintigraphy [18]. Our study used changes in tis-
sue compressibility and extracellular fluid load as early
indicators of lymphatic pathology. These subcutaneous
tissue changes are less specific to the lymph vessels them-
selves than lymphoscintigraphy. However, during analysis
of such changes when known moderating factors were
taken into account [23], there was adequate signal within
the data to support further exploration in larger studies
of longer duration.
Our study thus suggests that PC medications, delivered
at coverage levels consistent with WHO recommenda-
tions, may be sufficient to achieve reversal of covert tis-
sue changes. However, given the low rate of MDA
participation in this cohort, the risk of progression to
overt lymphedema may still persist for some of the par-
ticipants in this study. A more holistic approach to mor-
bidity prevention may be needed, including community-
wide education in hygiene protocols, and early self-care
should symptoms manifest. Country programmes may
need to make greater efforts to target young males with
gender appropriate education regarding the necessity to
participate in MDA activities, even if they do not see
themselves as being at risk. Adolescents and young adults
should be a focus of increased testing in highly endemic
areas as well as for increased promotion of behavioural
change interventions such as preventing mosquito bites to
avoid infection altogether.
Conclusion
Baseline comparison of LF antigen-positive and antigen-
negative young people showed significant and clinically
relevant covert differences in the superficial tissues among
the antigen-positive cases compared to negative controls.
These differences were no longer detectable six months
after consumption of PC. Thus, treatment was associated
with reversal over time of the previously observed effects
of infection. Longer follow-up of such cohorts is required
to confirm whether these improvements persist over time.
Low PC coverage as observed during the 2014 MDA
may miss many infected young people, as well as being
unlikely to interrupt disease transmission to those cur-
rently uninfected. Young people should be a focus of
increased education and awareness campaigns in endemic
areas. Indurometry and BIS have shown good reliability
to detect tissue changes in young people living in an LF-
endemic region in Central Myanmar. These methods
should therefore be considered in operational research
on, and implementation of, clinical services to fulfil the
second pillar of the GPELF.
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